An Investigation on the Effect of Age and BMI on the Pharmacokinetics of Transdermal Granisetron.
Phase of Trial: Phase I
Latest Information Update: 09 Jul 2013
At a glance
- Drugs Granisetron (Primary)
- Indications Nausea and vomiting
- Focus Pharmacokinetics
- 09 Jul 2013 Outcomes for part 2 of this trial presented at the Multinational Association for Supportive Care in Cancer (MASCC) 2013 Annual Meeting, according to a ProStrakan media release.
- 08 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 Oct 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.